RxDoctor Payments DataLook up a doctor →

Stuart Burgess, MD

Retina Specialist · Plantation, FLNPI 1689676363

Payments from drug & device makers

$4,601,277in general payments, 2019–2025

Across 721 payments — averaging $6381.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$3.6M
  • Kyowa Kirin, Inc.$346K
  • Bayer$294K
  • Hexal AG$143K
  • Regeneron$108K
  • Janssen Research & Development, LLC$32K
  • plus $48K from 33 others
$1,683in research payments, 2019–2025

Across 10 payments — averaging $168.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K

What the payments were for

  • Consulting fees$1,7259%
  • Travel & lodging$5,38429%
  • Food & beverage$9,34351%
  • Ownership interest$1,92610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,601,277 in reported general payments places this provider in the 95th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$2,656,493
Medicare patients
578
Services billed
149,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate89$2,779
Difluprednate14$1,675
Dorzolamide Hcl11$295
Ciprofloxacin Hcl14$178
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$175
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$170
Latanoprost22$137

Paid to pharmacies, not to this prescriber.

Other retina specialist in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →